10-QPeriod: Q3 FY2013

AbbVie Inc. Quarterly Report for Q3 Ended Sep 30, 2013

Filed November 12, 2013For Securities:ABBV

Summary

AbbVie Inc. reported its third-quarter and nine-month results for the period ending September 30, 2013, marking its first full year as an independent, publicly traded company following its spin-off from Abbott Laboratories on January 1, 2013. The company demonstrated solid top-line growth, with net sales increasing by 3% and 4% for the three and nine months, respectively, driven primarily by the strong performance of its flagship product, HUMIRA. Despite facing patent expirations for key products like TriCor and Niaspan, AbbVie's diversified portfolio and ongoing R&D efforts, particularly in expanding HUMIRA's indications and developing new therapies for chronic diseases, position it for continued growth. The company also managed its expenses effectively, with R&D spending seeing a decrease due to prior-year charges, though SG&A increased to support growth and the costs associated with operating as a standalone entity.

Financial Statements
Beta
Revenue$4.66B
Cost of Revenue$1.09B
Gross Profit$3.57B
SG&A Expenses$1.26B
Operating Expenses$3.29B
Operating Income$1.37B
Interest Expense$75.00M
Net Income$964.00M
EPS (Basic)$0.60
EPS (Diluted)$0.60
Shares Outstanding (Basic)1.59B
Shares Outstanding (Diluted)1.60B

Key Highlights

  • 1Net sales increased by 3% to $4.66 billion for the third quarter and 4% to $13.68 billion for the first nine months of 2013, demonstrating consistent revenue growth.
  • 2HUMIRA remained the primary growth driver, with sales up 19% to $2.77 billion in Q3 and 16% to $7.62 billion for the nine months, reflecting strong performance across multiple indications and geographies.
  • 3The company incurred $220 million in acquired in-process R&D expenses in Q3 2013, including significant collaboration agreements with Ablynx NV and Galapagos NV, indicating continued investment in pipeline development.
  • 4Operating earnings decreased by 14% to $1.37 billion in Q3 2013, largely due to higher SG&A expenses and acquired in-process R&D, despite revenue growth.
  • 5Net earnings saw a significant decrease to $964 million in Q3 2013 compared to $1.59 billion in Q3 2012, impacted by increased operating costs and the absence of a significant tax benefit recorded in the prior year.
  • 6AbbVie maintained a strong liquidity position, with cash and cash equivalents and short-term investments totaling $9.60 billion at September 30, 2013.
  • 7The company declared and paid a quarterly cash dividend of $0.40 per share in Q3 2013 and authorized a $1.5 billion stock repurchase program, signaling a commitment to returning capital to shareholders.

Frequently Asked Questions

The primary driver of AbbVie's revenue growth is its flagship product, HUMIRA. Sales of HUMIRA continued to show strong double-digit growth in both the United States and international markets, contributing significantly to the company's top-line performance.

AbbVie experienced a decline in sales for its lipid franchise, which includes TriCor, TRILIPIX, and Niaspan, due to the introduction of generic versions in the U.S. market. While these expirations negatively impacted sales in these specific product lines, the growth from HUMIRA and other products helped to offset these declines overall.

AbbVie is investing in its future through significant research and development (R&D) initiatives. This includes expanding indications for existing drugs like HUMIRA and entering into collaboration agreements with other companies, such as Ablynx NV and Galapagos NV, to develop new therapies for complex diseases. The company also recorded substantial acquired in-process R&D expenses related to these collaborations.

Despite a decrease in net earnings for the quarter due to increased operating expenses and the absence of prior-year tax benefits, AbbVie demonstrated solid revenue growth driven by HUMIRA. The company's strong cash position and ongoing investment in R&D suggest a positive outlook, though investors should monitor the impact of upcoming patent cliffs and the increasing SG&A costs associated with operating as a standalone entity.